Cambridge Healthtech Institute to Host Inaugural Molecular Diagnostics Europe

Sept. 17, 2010 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute, a premier information provider for the life sciences industry, will host its Inaugural Molecular Diagnostics Europe meeting on October 5-7, 2010 in Hannover, Germany.

Molecular diagnostic tools are driving biomedical research and the in vitro diagnostics market.  Clinical diagnosis has vastly improved with technological advances to enable speed, enhance sensitivity, and reduce costs based on quantitative and accurate measurements.

Cambridge Healthtech Institute’s Molecular Diagnostics Europe covers a complete array of tools, including next-generation sequencing, microarrays, quantitative PCR, microfluidics and point-of-care technologies. The conference program will focus on two diagnostic applications with widespread clinical impact: cancer and infectious disease.

Conference tracks include:

•  Moving Molecular Diagnostics from Bench to Bedside (October 5-6, 2010)
•  NGS: The Ultimate for Molecular Diagnostics (October 5-6, 2010)
•  Point-of-Care Diagnostics (6-7 October, 2010)

Keynote presentations include:

Linh Hoang, M.D., Ph.D., Director, Genomic Medicine, LIFE Technologies; Marjolein Kriek, M.D., Ph.D., Clinical Geneticist, Human and Clinical Genetics, Leiden University Medical Centre; Stephen Little, Ph.D., Vice President Personalized Healthcare, QIAGEN; Rudi Pauwels, Ph.D., Founding Director & CEO, Biocartis; and Rosanna W. Peeling, Ph.D., Professor, Diagnostics Research, London School of Hygiene & Tropical Medicine, Faculty of Infectious & Tropical Diseases, Department of Clinical Research.

In addition, interactive breakout discussion groups will be held on Tuesday, October 5, 2010.

Join a facilitated discussion group focused around scientific and technology related topics. This unique session allows conference participants to exchange ideas, experiences, and develop future collaborations around a focused topic. Topics include:

•  NGS and Data Quality for Diagnostic Applications
•  Sequencing Cancer Genomes: Potential Healthcare Applications
•  Circulating Tumor Cells and Cell Free Nucleic Acids: A Real Time Access to the Cancer Genome
•  What Does Success Look Like for an Infectious Disease Molecular Diagnostics Test, and Which of the Following Factors Drive This?
•  High-Throughput Protein Detection Technologies in Molecular Diagnostics of Cancer
•  NGS: Opportunities for Improving Oral Care Diagnostics: Translating Research to Practice

For more information about the conference, please visit http://MolecularDiagnosticsEU.com

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. http://www.chicorporate.com

For more information:

Olga Pavleyeva
Marketing Manager
Cambridge Healthtech Institute
(781) 972-5492
opavleyeva@healthtech.com

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.